Zoetis Inc. (ZTS)
Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Ascends But Remains Behind Market: Some Facts to Note
In the closing of the recent trading day, Zoetis (ZTS) stood at $172.24, denoting a +0.17% change from the preceding trading day.
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
Zoetis (ZTS) closed at $165.02 in the latest trading session, marking a +0.94% move from the prior day.
Zoetis (ZTS) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Wall Street Journal Vs. Zoetis
The Wall Street Journal released an article claiming that Zoetis' OA pain drug (Librela) is not safe. I go over these claims and explain why I believe they are unfounded. Librela might face a label change soon, but I don't think there's any reason to worry. I explain why.
Here's Why Zoetis (ZTS) Gained But Lagged the Market Today
Zoetis (ZTS) closed the most recent trading day at $164.84, moving +0.81% from the previous trading session.
Here's Why Zoetis (ZTS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The animal health industry is resilient, Zoetis CEO
Zoetis CEO Kristin Peck unpacks pet owners' concerns in caring for their beloved animals on 'The Claman Countdown.'
Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
Zoetis: Healing Paws, Growing Profits
Zoetis is active in multiple segments that are all expected to grow at a CAGR of 4% or more. The company has growing revenues, a strong balance sheet, a high FCF margin, and no major maturities. Librela, Solensia and Simparica Trio will drive the stock going forward.
